DNLI
Denali Therapeutics (DNLI)
$77
About Denali Therapeutics (DNLI)
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Details
Daily high
$25.31
Daily low
$23.51
Price at open
$23.76
52 Week High
$25.31
52 Week Low
$12.58
Market cap
3.8B
Dividend yield
0.00%
Volume
1.7M
Avg. volume
1.9M
P/E ratio
-8.35
Denali Therapeutics News
Details
Daily high
$25.31
Daily low
$23.51
Price at open
$23.76
52 Week High
$25.31
52 Week Low
$12.58
Market cap
3.8B
Dividend yield
0.00%
Volume
1.7M
Avg. volume
1.9M
P/E ratio
-8.35